ERBB3 and head and neck squamous cell carcinoma: Overall, these results demonstrated that HNSCC cell lines with different sensitivity to cetuximab contain a high percentage of EGFR‐, HER2‐, and HER3‐positive cells and that these receptors are generally highly expressed on these positive cells.